FindTrial
Sign In

Efficacy of Favipiravir (T-705) in patients infected with Ebola virus in Sierra Leone: a preliminary clinical trial

Efficacy of Favipiravir (T-705) in patients infected with Ebola virus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCN-15007272
Enrollment
Unknown
Registered
2015-10-16
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ebola virus disease (EVD)

Interventions

control:recommended therapy by WHO
T-705treatment:recommended therapy by WHO plus T705

Sponsors

Sierra Leone-China Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
9 Years to 66 Years

Inclusion criteria

Inclusion criteria: A non-randomization, double-blind was conducted as consideration for the large difficulty in Ebola patients management during this outbreak. Suspected cases were isolated in the ETC of Sierra Leone-China Friendship Hospital and tested for EVD. Confirmed patients were discriminated if they presented with an illness that met the case definition for EVD by WHO, and then were divided into two groups.

Exclusion criteria

Exclusion criteria: Patients who were during pregnancy,can not take oral medication.

Design outcomes

Primary

MeasureTime frame
Death and Survival;—

Secondary

MeasureTime frame
viral load;negative qualitative PCR after treatment;clinical Symptoms improvement;survival time;—

Countries

Sierra Leone

Contacts

Public ContactJiang Jiafu
15810174122@139.com+86 15810174122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026